Temporal endogenous gene expression profiles in response to lipidmediated transfection" (2015). Biological Systems Engineering: Papers and Publications. 515. https://digitalcommons.unl.edu/biosysengfacpub/515 DNA delivery provides a mechanism to directly alter endogenous gene expression and cellular behavior with applications in functional genomics [1], tissue engineering [2], medical devices [3] and gene therapy [4, 5] . Viruses and the profuse knowledge about the molecular mediators of viral infection [6] have been exploited to develop Abstract Background -Design of efficient nonviral gene delivery systems is limited as a result of the rudimentary understanding of the specific molecules and processes that facilitate DNA transfer. Methods -Lipoplexes formed with Lipofectamine 2000 (LF2000) and plasmid-encoding green fluorescent protein (GFP) were delivered to the HEK 293T cell line. After treating cells with lipoplexes, HG-U133 Affymetrix microarrays were used to identify endogenous genes differentially expressed between treated and untreated cells (2 h exposure) or between flow-separated transfected cells (GFP+) and treated, untransfected cells (GFP-) at 8, 16 and 24 h after lipoplex treatment. Cell priming studies were conducted using pharmacologic agents to alter endogenous levels of the identified differentially expressed genes to determine effect on transfection levels. Results -Relative to untreated cells 2 h after lipoplex treatment, only downregulated genes were identified ≥ 30-fold: ALMS1, ITGB1, FCGR3A, DOCK10 and ZDDHC13. Subsequently, relative to GFP-cells, the GFP+ cell population showed at least a five-fold upregulation of RAP1A and PACSIN3 (8 h) or HSPA6 and RAP1A (16 and 24 h). Pharmacologic studies altering endogenous levels for ALMS1, FCGR3A, and DOCK10 (involved in filopodia protrusions), ITGB1 (integrin signaling), ZDDHC13 (membrane trafficking) and PACSIN3 (proteolytic shedding of membrane receptors) were able to increase or decrease transgene production. Conclusions -RAP1A, PACSIN3 and HSPA6 may help lipoplex-treated cells overcome a transcriptional shutdown due to treatment with lipoplexes and provide new targets for investigating molecular mechanisms of transfection or for enhancing transfection through cell priming or engineering of the nonviral gene delivery system.
Introduction
very efficient viral gene delivery systems [7] . However, oncogenicity, immunogenicity, and the lack of repeated dosing capability [8] [9] [10] [11] of viruses have spurred research towards enhancing the efficacy of nonviral DNA carriers. Nonviral carriers such as cationic lipids (i.e. lipoplexes) [12] [13] [14] [15] [16] [17] [18] [19] [20] and polymers (i.e. polyplexes) [21] do not have the problems associated with viruses but suffer from low transfection. However, an incomplete understanding of the molecules and mechanisms that facilitate successful nonviral transfection precludes the efficient design of more efficient nonviral systems [19, [22] [23] [24] .
Towards a better understanding of nonviral transfection, transcriptome profiling has been used to identify the cellular and tissue response after treatment with nonviral gene carriers by comparing treated samples with untreated samples [23, [25] [26] [27] [28] [29] . For example, a previous study used microarrays to identify the in vivo cellular response to treatment of lipoplexes and found type I interferon to be upregulated in the spleen after treatment of polyethylene glycol-modified lipoplexes as a result of delayed endosomal escape. That study provided a molecular framework to redesign the DNA carrier for improved safety of the lipoplex, informed through comparison of the gene expression profiles of treated tissue to untreated tissue [7] . However, that work was limited in that molecules facilitating transfection were not identified (i.e. no comparison of gene profiles from treated and transfected cells to treated but untransfected cells was made) to provide a molecular basis to redesign the DNA carrier for improved transfection efficiency. Another study used microarrays to highlight the time-and vector-dependence of the gene expression profile of cells treated in vitro with lipoplexes, which showed different types of endogenous genes being over-and underexpressed at 8 h (stress-inducible, immune response, antiviral, cellular growth and division), 24h (cellular growth and division, G protein-coupled receptors, heat shock proteins, transcription/translation effectors, proteasome, senescence and cytoskeletal) and 48 h (cellular growth and division, transcription/translation effectors, Golgi-endoplasmic reticulum trafficking, heat shock proteins, DNA repair, cytoskeletal, and motility) [30] after DNA delivery, although, again, in that work, transfected cells were not studied in isolation and therefore the data provide information about cellular response to treatment with lipoplexes but not about mechanisms that facilitate transfection. Gene expression profiling has also been useful in assessing specific genes expressed by epithelial cells in vitro to cope with treatment-induced cytotoxicity and apoptosis, highlighting genes such as interleukin-9 receptor (IL-9R), heat shock protein 70 (HSP70) and met proto-oncogene precursor (cMET) upregulated in cells in lipoplex transfection [26] . Together, these previous studies show the usefulness of microarray analysis to identify genes and pathways elicited after treatment of cells or tissues with nonviral gene delivery systems and that the gene expression profile can vary drastically at various time points after treatment with lipoplexes. However, a substantial gap in knowledge remains about molecules and pathways used by cells to overcome the different barriers that occur over time during DNA transfer [21, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] .
To identify mechanisms that facilitate transfection (i.e. successful delivery of the transgene), a lipoplex-treated population of cells can be separated into two subpopulations (transfected and untransfected) and, subsequently, their transcriptome can be profiled using microarray analysis. When transfected and untransfected gene expression profiles are compared, the identified differentially expressed genes provide insight into molecules and mechanisms that facilitate transfection [44, 45] . For example, in our previously published study, we showed RAP1A and HSPA6 endogenous genes to be overexpressed in transfected human embryonic epithelial kidney (HEK 293T) cells 24 h after delivery of the GFP transgene using lipoplexes [45] or polyplexes [44] , compared to treated but untransfected cells. Subsequently, priming cells for transfection by altering RAP1A or HSPA6 endogenous levels prior to polyplex or lipoplex treatment, respectively, resulted in an up to 2.5-fold increase in transfection [44, 45] . Those studies demonstrated that transfection can be improved by targeting specific molecules that are over-or under-expressed in transfected cells compared to untransfected cells. Although targeting a single barrier or step in DNA transfer often leads to improved transfection [46] , it is unlikely that consideration of a single endogenous gene in DNA carrier design will lead to a therapeutically relevant transfection system. Instead, multi-faceted approaches generally lead to improved transfection [47] , although the genes and pathways implicated at other, earlier stages of transfection (e.g. internalization, endosomal escape, nuclear localization, nuclear entry) [21, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] remain unidentified and prevent the design of efficient gene delivery systems. Because lipid and polymer DNA carriers have shown promising in vitro and in vivo transfection [47] , the aim of the present study is to identify genes and pathways implicated at these earlier stages for lipid vectors, whereas our other work focuses on polymer vectors [48] .
The objective of the present study was to identify endogenous genes differentially expressed at 2, 8, 16 and 24 h after delivery of the GFP transgene to HEK 293T cells using a cationic lipid vector (Lipofectamine 2000; LF2000). Relative to untreated cells, transcriptome profiling of HEK 293T cells at 2 h post-delivery of lipoplexes was used to identify those endogenous genes that may act in response to treatment stress such as toxicity induced by the complex [22] or inherent intracellular defenses against foreign nucleic acids [49] . Relative to GFP-cells, transcriptome profiling was used to identify those endogenous genes used by transfected cells (GFP+) that may aid in overcoming cellular barriers known to occur during DNA transfer [21, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] at 8, 16 and 24 h post-delivery of lipoplexes. Events that typically take place 8 h after delivery of complexes to the cells include a high rate of endosomal escape [31, 33] , unpacking of plasmid DNA (pDNA) from vector [31, 32] , some nuclear localization of complexes or pDNA [31, [33] [34] [35] [36] , very small amounts of nuclear internalization of complexes or pDNA [34, 36, 37] and very little production of transgenic protein [34, 38] . Events that typically take place 16 h after delivery of complexes to the cells include high rate of nuclear localization of complexes or pDNA [34, 36] , continued nuclear internalization of complexes or pDNA [21, 34, 36, 37] and continued production of transgenic proteins [34, 38] . Events that take place 24 h after delivery of complexes to the cells include the continued nuclear internalization of pDNA [34, 36, 37, 40] , the highest synthesis of transgenic proteins [34, 38, 40] and mitosis (including distribution of transgenic proteins and pDNA to daughter cells) [36, 39] . Therefore, the time points chosen for the investigations in the present study were selected to capture several key cellular events that occur throughout the gene delivery process. We also ascertained the potential role of several of the identified genes for their ability to affect transfection by use of pharmacologic activators or inhibitors of the target endogenous gene. The endogenous genes and pathways that facilitate transfection as identified in the present study can be used as targets for increasing transfection through cell priming or for improved DNA carrier design.
Materials and methods

Cell culture and plasmid preparation
HEK 293T cells (ATCC, Manassas, VA, USA) were cultured in T-75 flasks in Dulbecco's modified Eagle's medium containing 4.5 g/l glucose, supplemented with 10% fetal bovine serum, 1mM sodium pyruvate, 100 units/ml of penicillinstreptomycin (all Gibco, Carlsbad, CA, USA) and maintained at 37°C in a humidified 5% CO 2 atmosphere. For seeding, cells were dissociated at confluence with 1mM ethylenediaminetetraacetic acid (EDTA) and viable cells were counted using a hemocytometer and trypan blue dye exclusion assay. Plasmid pEGFP-LUC encodes both the enhanced green fluorescent protein (EGFP) and firefly luciferase protein (LUC) under the direction of a cytomegalovirus promoter (Clontech, Mountain View, CA, USA), and was used for transfection experiments (see below). Plasmid was purified from bacteria culture using Qiagen (Valencia, CA, USA) reagents and stored in Tris-EDTA buffer solution (10mM Tris, 1mM EDTA, pH 7.4) at -20°C.
Transfection and sample isolation for microarray
Cells were seeded at a density of 44.8×10 3 cells/cm 2 into multiple T-75 flasks. After adherence (approximately 18 h after seeding), lipoplexes were formed using LF2000 in accordance with the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). Briefly, LF2000 transfection reagent diluted in serum-free Opti-MEM media (Invitrogen) was added dropwise to DNA diluted in Opti-MEM at a lipid: DNA ratio of 1.5:1, mixed by gentle pipetting, and incubated at room temperature for 20 min. After forming the lipoplexes, they were delivered to the media above the cells to deliver 0.15 μg/cm 2 of DNA. Those transfection conditions were optimal for high transfection (typically 70-90%) and low cytotoxicity with optimization performed as described previously [45] . The complexes remained in contact with the cells for the duration of each experiment: 2, 8, 16 and 24h. After the incubation period of the lipoplexes at each time point, cells were dissociated using 0.05% Trypsin-EDTA (except only EDTA for the 2-h condition) and suspended in 1X phosphate-buffered saline (PBS) at 2-5 million cells/ml and placed on ice. For the 2-h time point, because very little GFP had been produced, untreated samples were obtained identically, as were the treated samples, except no lipoplexes were delivered to the cells. For the 8-, 16-and 24-h time points, after dissociation, the treated cells were separated into transfected (GFP+) and untransfected (GFP-) pure cell populations using fluorescence activated cell sorting (FACS), as described previously [45] . Briefly, at 8, 16 or 24 h after the addition of complexes, cells were dissociated, counted, and concentrated in 1X PBS and placed on ice, as described above. Flow cytometric analysis was performed using a B-D FAC-SVantage SE three-laser, high speed cell sorter (University of Nebraska-Lincoln's Center for Biotechnology Flow Cytometry Core Facility) equipped with a 530/15 nm SE laser. A live gate was set on the GFP+ cell population in forward scatter versus side scatter plot to remove cell debris or clumped cells from the sort. A minimum of 2×10 6 cells for each population (GFP+, GFP-) was collected. Cells were collected at each time point on three different days providing the following independent samples (n=3 for each sample): 2 h treated, 2 h untreated, 8 h GFP+, 8 h GFP-, 16 h GFP+, 16 h GFP-, 24h GFP+ and 24 h GFP-(for an overview of the experimental design, see Figure 1 ). RNA from each sample was then extracted, purified and hybridized to microarrays (see below).
RNA extraction and microarray hybridization
RNA extraction and quality check was performed as described previously [45] . Briefly, after obtaining each sample (24 in total: three each for 2 h treated, 2 h untreated, 8 h GFP+, 8 h GFP-, 16 h GFP+, 16 h GFP-, 24 GFP+ and 24 h GFP-; see also above and Figure 1 ), total RNA was TRIzol extracted and further purified using a Qiagen RNeasy column (Qiagen) to achieve a 260/280 ratio greater than 1.8 on Nanodrop 2000 (Thermo Scientific, West Palm Beach, FL, USA). After quality assessment using an RNA 6000 Nano LabChip on an Agilent BioAnalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA), purified RNA was reverse transcribed to cDNA and hybridized to Affymetrix GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA) overnight at 45°C, in accordance with the manufacturer's instructions. After streptavidin-phycoerythrin conjugate staining, expression data were read with the GeneChip Scanner 3000 7G (Affymetrix) to obtain the expression data of over 47 000 transcripts and variants annotated for all known genes of the human genome. Affymetrix GeneChip Operating Software (GCOS, version 1.3) was used for washing, scanning and basic data analysis, including calculation of absolute values and normalization of the data with respect to internal standards.
Microarray and bioinformatics analyses
Each microarray provides 11 independent measures of gene expression (n=11) for over 47,000 transcripts and variants annotated for all known genes of the human genome.
Figure 1.
Overview of the experimental design (see Materials and methods). HEK 293T cells were seeded and allowed to become adherent (approximately 18 h). Then, lipoplexes were formed and delivered to adherent cells and allowed to remain in contact for 2, 8, 16 or 24 h. At the 2-h time point, treated cells were harvested and RNA was extracted and hybridized to microarrays. The treated profile was compared with cells that underwent the same treatments, except no lipoplexes were delivered. At the 8-, 16-or 24-h time points, treated cells were FACS separated into GFP positive (GFP+; transfected) and GFP negative (GFP-; untransfected) cell populations and RNA was extracted and hybridized to microarrays. The process was repeated on separate days to achieve n=3 for each population at each time point.
Microarray expression data were background adjusted and normalized [50] and quality tested using R/Bioconductor with the AffyCoreTools library package, with all arrays showing good hybridization quality, as described previously [44, 45] . The gene expression data has been deposited at the NCBI Gene Expression Omnibus (GEO) accession GSE59666. Differentially expressed genes between treated and untreated (2-h time point) or GFP+ and GFP-(8-, 16and 24-h time points) were determined using a nonparametric mean-variance smoothing method developed for R programming environment [51] . Microarray data for the 24-h time point were collected previously and analyzed using linear models [45] and were downloaded from GEO accession GSE20615. Those microarrays were again analyzed here, using the nonparametric smoothing method, which resulted in a larger gene set differentially expressed between GFP+ and GFP-gene expression profiles than has been previously reported. Those results are included in the present study, along with the pathways and ontologies enriched to the new gene set (see below). Genes differentially expressed greater than two-fold and posterior probability greater than 0.99 were used for the bioinformatics analysis. Enrichr [52] , an open source and freely available gene list enrichment analysis tool, was used to identify enriched pathways for Kyoto Encyclopedia of Genes and Genomes (KEGG) [53] , WikiPathways (WIKI) [54] , BioCarta [55] , protein-protein interacting proteins (PPI Hub Proteins) [56] , The Comprehensive Resource of Mammalian Protein Complexes (CORUM) [57] , Reactome [58] and Gene Ontology Process (GO) [59] . Each list of differentially expressed genes was uploaded to the Enrichr [52] website and pathways or ontologies enriched greater than a combined score of 5 were reported. The combined score is computed by taking the log of the p-value from the Fisher's exact test multiplied by the Z-score of the deviation from the expected rank [52] . Among the differentially expressed genes, the most promising genes that may affect transfection were identified. The genes were selected based on high differential expression, putative gene role and potential to play a role in processes that are known to occur during DNA transfer [21, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] , and exploratory gene association network (EGAN) analysis [60] . EGAN analysis was performed as previously described [44] but, briefly, the tool was used to visualize common occurrences among gene-gene interactions and enriched pathways/ontologies [60] and aided in selecting genes to study further (see Supporting information, Figure S1 ). After identifying target genes, the NextBio [61] Pharmaco Atlas was used to identify pharmacologic agents known to upregulate or downregulate the target gene with a score above 70. Those pharmacologic agents were then used for transfection studies in the presence of pharmacologic agents (see below).
Transfection in the presence of pharmacologic agents
These experiments were performed as previously described to alter the expression of endogenous target genes identified from microarray analysis [45] . The studies acted primarily as a screening tool to confirm whether a particular gene plays an important role in the DNA transfer process. Briefly, transfection studies were performed in the presence and absence of pharmacologic activators or inhibitors of the target genes (selected as described above). HEK 293T cells were seeded in 48-well plates at 44.8×103 cells/ cm2 and, 18h later, pharmacologic agents were delivered to the media on the cells to achieve the final desired drug concentration. The pharmacologic agent was allowed to incubate for 1 h, and then lipoplexes were formed (as described above) and delivered to the media above the cells (still containing the pharmacologic agent). The pharmacologic agent and lipoplexes remained in contact with the cells for the next 24 h and then the cells were lysed and transfection levels were quantified by measuring the luciferase activity (relative light units) using the Luciferase Assay System (Promega, Madison, WI, USA) and luminometer (Turner Designs, Sunnyvale, CA, USA), and luciferase activity was normalized to the total protein amount determined with the BCA protein assay (Pierce, Rockford, IL, USA) and compared with transfection levels in vehicle-only control cells. The results were reported as the fold-change to eliminate variability in absolute measures of transfection, respectively, for ALMS1, ITGB1, FCGR3A, DOCK10, PACSIN3 and ZDDHC13 genes; pharmacologic activators included phenethicillin [62] , 1,10-phenanthroline [63] , ritonavir [64] , nifenazone [62] , hydralazine hydrochloride [62] , β-acetylγ-O-hexadecyl-l-α-phosphatidylcholine hydrate (B-AGO-PCL) [65] ; and pharmacologic inhibitors included quipazine [62] , artemisinine [64, 66] , gentamicin [64] , 8-methoxypsoralen [62] , valsartan [64] and nicergoline [62] (all from Sigma-Aldrich, St Louis, MO, USA). The concentrations of the pharmacologic agents selected for the present study were comparable to those tested in the literature showing gene activity [62, [64] [65] [66] but were optimized for high transfection and minimal toxicity (not shown) (see Supporting information, Figure S2 ). Statistical analysis was performed using Prism, version 5 (GraphPad, La Jolla, CA, USA) using Student's t-test at a 95% confidence level. Data are reported as the mean±SEM (n=3).
Results
The GFP transgene was delivered to HEK 293T cells using LF2000 transfection reagent. Then, 2 h after delivery of the lipoplexes, the initial cell response was determined using microarray analysis. Changes in the transcriptome were identified by comparing gene expression profiles of cells treated with lipoplexes with cells not treated by lipoplexes ( Figure 1 ). All genes found to be differentially expressed two-fold or greater are listed in the Supporting information (Table S1 ). Among the greatest differentially expressed genes in treated cells compared to untreated cells were: ALMS1, ITGB1, FCGR3A, DOCK10 and ZDDHC13, which were downregulated 34.5-, 35.7-, 38.5-, 43.5-and 50.0-fold, respectively (Table 1) . Among all genes differentially expressed between treated and untreated cells at the 2-h time point (see Supporting information, Table S1 ), only LIMS1 and ITGB1 were found to be enriched to cellular pathways including cell migration, the inflammatory response, cell adhesion and cell junctions ( Table 2) . Taken together, treated cells were shown to undergo rapid transcriptional changes in response to treatment with lipoplexes in a highly downregulated manner.
Because most cells internalize lipoplexes within the first few hours of exposure [21, 31, 33, 34, [41] [42] [43] ; Sarah A. Plautz (S.A.P) unpublished results] but not all cells actually express the transgene, we next set out to identify those endogenous genes that may facilitate transfection. To do so, lipoplexes were delivered to the cells and, after 8, 16 or 24 h, the treated cell population was sorted into transfected GFP+ and GFP-subpopulations ( Figure 1 ). Using microarray analysis, changes in the transcriptome were identified by comparing GFP+ and GFP-endogenous gene expression Fold change indicates differential expression of HEK 293T cells transfected with pEGFPLuc/LF2000 microarrays (n=3) compared to untreated microarrays (n=3) with a posterior probability greater than 0.99 at the 2-h time point. Negative numbers indicate downregulation. NA: not available. Genes found in Table 1 and the Supporting information (Table S1 ) were found to be over-represented to specific terms. The first column indicates the source of pathway database; the second column lists the enriched term; the third column lists the enrichment score; and the last column indicates which of the differentially expressed genes belong to the enriched term. Downregulated genes are shown in italic, and genes greater than five-fold differentially expressed are shown in bold. For a description of the source or score, see Materials and methods.
profiles. All genes found to be differentially expressed twofold or greater are listed in the Supporting information (Table S1). At the 8-h time point, the greatest differentially expressed genes were RAP1A and PACSIN3, both upregulated 38.62-or 6.64-fold, respectively (Table 3) . At the 16-h time point, the greatest differentially expressed genes were RAP1A and HSPA6, upregulated 17.30-or 7.42-fold, respectively (Table 3) . At the 24-h time point, the greatest differentially expressed genes were once again RAP1A and HSPA6, upregulated 10.28-or 11.35-fold, respectively (Table 3) . We were next interested in understanding how the gene expression profile changes over time, in terms of the number of genes expressed, as well as which genes were found to be differentially expressed over multiple time points. The number of genes differentially expressed (between GFP+ and GFP-) increased from 8 h to 16 h from seven genes to 27 genes, respectively ( Figure 2 ). ARMC8, ATF3 and RAP1A genes were commonly expressed between the two time points ( Figure 2 ). The number of genes differentially expressed decreased from 16 h to 24 h from 27 genes to two genes ( Figure 2 ), respectively, with HSPA6 and RAP1A genes commonly being expressed between the two time points ( Figure 2 ). RAP1A showed sustained upregulation in the transfected cell population compared to untransfected cell population at the 8-, 16-and 24-h time points ( Figure  2 ; see also Supporting information, Table S1 ). The largest number of genes differentially expressed occurred 16 h after exposure to lipoplexes in the transfected cell population.
To determine the role of all differentially expressed genes in transfected cells at each time point (8, 16 and 24 h; see Supporting information, Table S1 ), we performed a pathway and ontology enrichment analysis (Table 4 ; see Materials and methods). Pathways enriched from genes differentially expressed at the 8-h time point were the mesenchymal-epithelial transition (MET) and integrin pathways, protein complexes (CLTH, HSPA1A and SMARCA4) and GO processes involved in metabolism, proteolysis and catabolism (Table 4) . Pathways enriched at the 16-h time point were spindle and cell cycle pathways, as well as protein complexes involved in cell adhesion (RIAM-Rap1-GTP complex), proliferation (CDC2-PCNA-CCNB1-GADD45A complex) and stimuli response (MAPK9) ( Table 4 ). Pathways enriched at the 24-h time point were focal adhesion, migration, MET, integrin and stimuli response (mitogen-activated protein kinase, IL-3, type I interferon, unfolded protein response) pathways, along with protein complexes involved in paracrine signaling (HGFR), GTPase activity, transport (GABARAPL2) and cell adhesion (RIAM-Rap1-GTP complex) ( Table 4 ). Taken together, the pathways and ontologies enriched at each time point may play a role in transfection, and those genes differentially expressed greater than five-fold at each time point may play a significant role in those processes because Comparison of GFP+ to GFP-gene expression levels. Differential expression greater than or less than 1 represents upregulation or downregulation, respectively. Data represent genes differentially expressed comparing transfected microarrays (n=3) with treated, untransfected microarrays (n=3) with a posterior probability greater than 0.99 and differential expression greater than five-fold. The Supporting information (Table S1 ) lists all genes differentially expressed greater than two-fold. Figure 2 . The overlap of genes differentially expressed between the GFP+ and GFP-gene expression profiles is shown for each time point. Data represent genes greater than two-fold differentially expressed comparing transfected microarrays (GFP+; n=3) with treated, untransfected microarrays (GFP-; n=3) with a posterior probability >0.99. The level of differential expression for each gene is provided in the Supporting information (Table S1 ).
they are highly upregulated: 8 h (PACSIN3 and RAP1A), 16 h (RAP1A and HSPA6) and 24 h (RAP1A and HSPA6) ( Table 4 ).
As reported in the present study, microarray analysis revealed genes highly differentially expressed in treated cells compared to untreated cells at the 2-h time point and in GFP+ cells compared to GFP-cells at the 8-, 16-and 24-h time points (Tables 1 and 3 ). To discriminate whether any of the genes identified in the present study have a potential role in transfection as opposed to genes expressed as a treatment effect, pharmacologic studies were conducted. Those genes highly differentially expressed at the 2-, 8-, 16-or 24-h time points (Tables 1 and 3 ) were narrowed to a smaller subset to further test based on literature review of each gene's putative function, potential role in the DNA transfer process and exploratory gene association network analysis [60] (see Supporting information, Figure S1 ; Materials and methods). Highly differentially expressed genes RAP1A and HSPA6 (Table 3) were not studied using pharmacologic agents because we have previously shown that perturbing those genes prior to lipoplex delivery can enhance transfection by up to 2.5-fold [45] . The list of genes was narrowed to ALMS1, ITGB1, FCGR3A, DOCK10, PACSIN3 and ZDDHC13. Pharmacologic agents known to activate or inhibit each gene were found using NextBio [61] and from previous studies in the literature [62] [63] [64] [65] [66] , and were used as a screening tool to confirm whether a particular gene may play an important role in the DNA transfer process. The effect of the pharmacologic agent on transfection levels are summarized in Table 5 , with transfection levels provided in Figure 3 . In all pharmacologic studies reported here, no cytotoxicity was observed (see Supporting information, Figure  S2 ) with the exception of artemisinin (1mM) and nifenazone (5mM), where minor toxicity was observed (see Supporting information, Figure S2 ).
When the ALMS1 gene was activated (phenethicillin) or inhibited (quipazine), prior to delivery of lipoplexes, transfection levels were reduced by 7.6-fold or increased by 1.3fold, respectively ( Figure 3 and Table 5 ). Similarly, when the Selected enriched terms are listed for differentially expressed transcripts comparing GFP+ microarrays to GFP-microarrays at each indicated time point after delivery of pEGFPLuc/LF2000 complexes to HEK 293T cells. The first column indicates the name of pathway database; the second column lists the enriched term; the third column lists the enrichment score; and the last column indicates which of the differentially expressed genes belong to the enriched term. Downregulated genes are shown in italic, upregulated genes are underlined, and genes greater than five-fold differentially expressed are shown in bold. For a description of the source or score, see Materials and methods.
ITGB1 gene was activated (1,10-phenanthroline) or inhibited (artemisinine), transfection levels were increased by 1.3-fold or reduced by 5.8-fold, respectively ( Figure 3 and Table 5 ).When the FCGR3A gene was activated (ritonavir) or inhibited (gentamicin), transfection levels were increased by 1.3-fold or decreased by 2.5-fold, respectively ( Figure 3 and Table 5 ). When the DOCK10 gene was activated (nifenazone) or inhibited (8-methoxypsoralen) transfection levels were increased by 1.3-fold or decreased by 1.4-fold, respectively ( Figure 3 and Table 5 ). When the PACSIN3 gene was activated (hydralazine) or inhibited (valsartan), transfection levels were decreased by 1.3-fold or increased by 1.5-fold, respectively ( Figure 3 and Table 5 ). When the ZD-DHC13 gene was activated (β-acetyl-γ-O-hexadecyl-l-αphosphatidylcholine hydrate) or inhibited (nicergoline), transfection levels were decreased by 1.1-fold or decreased by 1.9-fold, respectively ( Figure 3 and Table 5 ). Taken together, altering ALMS1, ITGB1, FCGR3A, DOCK10, PACSIN3 or ZDDHC13 gene activity can affect transfection, showing that microarray analysis can identify genes possibly playing a role in transfection.
The effect of the concentration of the pharmacologic agents on transfection used to activate ALMS1 or inhibit ITGB1 or FCGR3A was evaluated next (Figure 3 ) because those agents had the largest impact on transfection. For phenethecillin (ALMS1 activation), the effect of reduced transfection from the pharmacologic treatment became less apparent as the concentration of the drug decreased: at 10 mM, 100 μM and 1 μM, transfection was reduced by 7.60±0.01-, 1.37±0.14-and 1.17±0.02-fold, respectively ( Figure 4 ). For artemisinine (ITGB1 inhibition), the effect of reduced transfection from the pharmacologic treatment also became less apparent as the concentration of the drug decreased: at 1 mM, 500 μM, 100 μM and 1 μM, transfection was reduced by 5.78±0.01-, 2.72±0.11-, 1.72±0.04-and 1.19±0.04-fold, respectively (Figure 4 ). For gentamicin (FC-GR3A inhibition), the effect of reduced transfection from the pharmacologic treatment became less apparent as the concentration of the drug decreased: at 10mM, 1mM and 10 μM, transfection was reduced by 2.49±0.04-, 1.18±0.12and 1.15±0.09-fold, respectively (Figure 4 ).
Discussion
Understanding the intracellular molecules and pathways that may facilitate DNA transfer provides insight into the potential mechanisms required for efficient transfection 
ZDDHC13
Palmoylates membrane proteins in Golgi apparatus to B-AGO-PCL 10 μM ↑ [65] CHCl 3 -11 regulate membrane-to-membrane trafficking [108] or Nicergoline 50 μM ↓ [62] DMSO -19 influence interaction of membrane proteins within lipid rafts [109, 110] , including Ras GTPases such as RAP1 [109] a. Effect of pharmacologic agent on gene or protein activity as reported in the literature: ↑, activation; ↓, inhibition. b. Transfection fold change comparing cells treated with pharmacologic agent with cells treated with vehicle only (Control+) (Figure 3 ). Transfection levels were measured 24 h after delivery of complexes to HEK 293T cells. The concentration of the pharmacologic agent was selected forminimal cytotoxicity and maximal effect (see Supporting information, Figure S2 ) [67], offering targets for designing enhanced nonviral gene delivery systems. Gene transfer requires molecular mediators to actively transfer the delivered DNA [33] through intracellular barriers, into the nucleus [31, [68] [69] [70] [71] [72] [73] [74] [75] [76] and for transgene expression [77] . Although the routing kinetics of the lipoplex have been observed as they occur over time (Table 3) to activate (underlined text) or inhibit (plain text) indicated genes. After a 1-h incubation period, lipoplexes were delivered and transfection levels were assayed after 24 h (see Materials and methods). Data are reported as the mean±SEM (n=3) and significant changes between treated and vehicle-only transfection levels are indicated as: * p<0.05 ; ** p<0.01 ; or *** p<0.001. and enable the development of transfection models [34, 40, 46, 78, 79] , the molecular mediators used by the cell to route the DNA complex are poorly understood. In the present study, we attempted to fill that gap in knowledge using a transcriptomics approach aimed at identifying molecules and pathways involved in key cellular events known to influence transfection at 2, 8, 16 and 24 h after lipoplex delivery. Because mRNA metabolism and catabolism can be condition-and cell-specific and the mRNA half-life widely varies from approximately 10 min to 10 h or more, our approach may miss the identification of molecules involved in short-lived signaling pathways. To address this challenge of using microarrays and a few selected time points, we integrated the identified endogenous genes and pathways from the present study with other studies that identified shortlived signaling events into a proposed preliminary model of the biology of transfection of HEK 293 T cells by lipoplexes ( Figure 5 ). The endogenous genes and pathways are discussed below in the context of the cellular processes and timing of those processes that occur during DNA transfer.
Treatment of cells with lipoplexes results in a cellular downregulation of transcription
In the present study, gene expression profiles were obtained for HEK 293T cells that were treated with lipoplexes for 2 h compared to untreated cells. Our results show a marked downregulation of 44 genes compared to untreated cells (Table 1 ; see also the Supporting information, Table S1 ) affecting cellular pathways in junction, adhesion, migration and inflammation ( Figure 5 and Table 2 ). During this period, the treated cells have been reported to internalize lipoplexes into endosomes and lipoplexes attempt to escape the endosome [22, 34, 40] at the same time as the cell is actively coping with the cytotoxic stress induced by lipoplexes or foreign DNA [80] ( Figure 5 ). Various strategies have been devised to reduce the cytotoxicity, such as maturation time for forming lipoplexes, DNA to liposome ratio, size of lipoplexes and serum-free cell culture conditions [80, 81] . However, one recent study advocates a molecular method to reduce cytotoxicity, based on knowing what gene is involved in the toxicity [7] and we advocate the use of a molecular basis to guide the design of improved DNA delivery systems with enhanced transfection [44, 45] . Because all of the genes identified in the present study at the 2-h time point were highly downregulated, the cellular response to exposure of lipoplexes is suggestive of a type of cellular shutdown of transcription, presumably to prevent further cytotoxic assault [22] and further uptake of foreign DNA [80] . We also noted that total RNA was reduced in cells treated with lipoplexes compared to untreated samples (data not shown), providing further evidence for a transcriptional shutdown. The transcriptional shutdown in response to short-term stress is reported to occur in other eukaryotic systems that act to rapidly destabilize mRNAs and coordinate mRNA turnover within a few minutes to achieve a strong activity of stress genes [82] . In the present study, we identified those genes that may play a role in processes that occur in HEK 293T cells after a 2-h exposure to lipoplexes; specifically, ALMS1, ITGB1, DOCK10, FCGR3A and ZDDHC13 genes ( Figure 5 and Table 1 ), which are discussed below in terms of potential hallmarks of the cell shutdown. However, whether the shutdown event is positive or negative for transfection is unclear given the effects of pharmacologic activation of target genes, as discussed below (Table 5 and Figure 3 ). The results from our studies demonstrate that there are many genes responsible for DNA transfer at different time points and that activating or inhibiting a single gene is unlikely to have a prodigious effect on DNA transfer, agreeing with our pharmacologic studies. During the first few hours after lipoplex treatment, filopodia have been reported to play a pivotal role in cellular binding and processing of lipoplexes and polyplexes prior to cellular entry via endocytosis [83, 84] . Filopodia are slender, actin-rich protrusions that extend outward from the cell body to sense the extracellular environment. Three genes identified in the present study (ALMS1, FCGR3A and DOCK10) are implicated in the generation of such podia protrusions ( Figure 5 ). ALMS1 is ubiquitously expressed and involved in centriole formation and stability [85] , the cell cycle [86] and ciliogenesis [87] , and contains two nuclear localization sequences [88] , which are all cellular processes or molecules that play a role in transfection [37, 39, 83] . Because the cellular response at 2 h was to downregulate the ALMS1 gene (Table 1) , the cell may be acting in defense as a result of exposure to foreign DNA by preventing the further uptake of lipoplexes via cilia. Hence, we hypothesized that activating ALMS1 with phenethicillin (penicillin analog) [62] prior to the delivery of lipoplexes would enhance cilia-mediated endocytosis [83, 87] and cell cycle processes [39, 86] leading to enhanced transfection. Similarly, we hypothesized that inhibiting ALSM1 with quipazine (serotonin reuptake inhibitor) [62] prior to lipoplex delivery would lead to decreased transfection. By contrast to our hypothesis, activating ALMS1 lead to a drastic reduction in transfection (7.6-fold) ( Table 5 ) in a dose-dependent manner (Figure 4) , at the same time as inhibiting ALMS1 slightly increased transfection (1.3-fold) ( Table 5 ). The conflicting result to our hypothesis highlights: (i) that nonspecific pharmacologic agents for ALMS1 may not be able to adequately test our hypothesis; (ii) that there is a potentially larger role of ALMS1 beyond transfection because cilia and basal bodies are involved in many inter-and intracellular processes [89, 90] ; or (iii) that cilia-mediated endocytosis results in an intracellular fate of the lipoplex leading to altered degradation of the lipoplex [91] . In any event, altering ALMS1 levels may drastically impact transfection.
FCGR3A, also implicated in the generation of podia [92] that have been shown to facilitate endocytosis of lipoplexes [83] , was identified as highly downregulated (Table 1) regulate actin, myosin, membrane fusion and the production of reactive oxygen intermediates during phagocytosis of immunoglobulin (Ig)G-opsonized particles [93] by leukocytes [94] . Although HEK 293T is not a leukocyte cell line, the FCGR3A receptor can also be found on embryonic epithelial cells [94] and maintain the necessary cellular machinery for endocytosis without exhibiting respiratory burst [95] . Activation of the receptor can lead to increased proliferation [94] and has been reported to enhance viral infection [96] . Hence, because of those studies and the impact of podia and endocytosis on transfection [83] , we hypothesized that activation of FCGR3A with the antiretroviral ritonavir [64] would lead to increased endocytosis of lipoplexes and therefore increase transfection. Similarly, we hypothesized that inhibition of FCGR3A by gentamicin (aminoglycoside antibiotic) [64] prior to delivery of lipoplexes would lead to reduced transfection. In support of our hypotheses, activating FCGR3A increased transfection slightly (1.3-fold) (Table 5) at the same time as inhibiting FCGR3A drastically reduced transfection (2.5-fold) ( Table 5 ) in a dose-dependent manner (Figure 4 ). The distribution of FCGR3A receptor in HEK 293T cells should be verified, and the exact mechanisms of FCGR3A in transfection of HEK 293T cells remain unclear. However, the results advocate a role of FCGR3A in lipoplex-mediated transfection.
DOCK10, also implicated in the generation of podia that have been shown to facilitate endocytosis of lipoplexes [83] ,was identified as being highly downregulated (Table 1) 2 h after exposure of HEK 293T cells to lipoplexes. DOCK10 contains a guanine nucleotide exchange factor domain, which activates GTPases (such as RAP1A as discussed below) with anti-apoptotic function, promotes actin cytoskeleton reorganization and proliferation [97] , and enhances motility via lamellipodia protrusions [98] . Because DOCK10 function agrees with observations correlated with transfection, such as endocytosis of lipoplexes via podia [83] , DNA repair and activation of protein folding chaperones [44, 45] , cell cycle [39] , and cytoskeletal signaling [99] , we hypothesized that activation (by nifenazone, a nonsteroidal anti-inflammatory agent) [62] or inhibition (8-methoxypsoralen, a selective inhibitor of DNA synthesis) [62] of DOCK10 prior to delivery of lipoplexes would lead to enhanced or decreased transfection, respectively. The results reported in the present study support our hypotheses, with activation or inhibition of DOCK10 enhancing or reducing transfection by 1.3-or 1.4-fold, respectively (Table 5) .
Another gene significantly downregulated in cells after 2 h of exposure to lipoplexes was ITGB1 (Table 1) , a ubiquitously expressed adhesion antigen [100] , which regulates immune cell chemotaxis [101] and the inflammatory response after infection [102] (Figure 5 ). Because the activation of ITGB1 mediates proliferation and inhibits apoptosis [103] and increased cell proliferation is associated with increased transfection [39] ,we hypothesized that activation (1,10-phenanthroline, uncouples oxidation from phosphorylation in metabolic cycle) [63] or inhibition (artemisinine, an antimalarial drug) [64, 66] of ITGB1 would increase or decrease transfection, respectively. Indeed, activating ITGB1 prior to delivery of lipoplexes resulted in a 1.3-fold increased transfection (Table 5) , which could be a result of its known effect on proliferative capacity of the cells and therefore increased transfection [39] . Similarly, inhibiting ITGB1 prior to delivery of lipoplexes resulted in drastically reduced transfection (5.8-fold) ( Table 5 ) in a concentrationdependent manner (Figure 4) , which could be a result of the reduced capacity of ITBG1 to prevent necrosis [102] and toxicity induced by the lipoplex [80] , which has been shown to inhibit transgene expression [104] . The ability of ITGB1 to drastically alter transfection provides evidence that ITGB1 may be involved in lipoplex-mediated gene delivery and agrees with one study suggesting that lipoplexes electrostatically interact with negative regions of activated β-integrins [105] to piggyback internalization along with the activated integrins. It was advocated that adhesion receptors, in general, serve as natural cell surface receptors for lipoplexes [105] along with other groups showing intercellular cell-adhesion molecule-1, syndecans [106] and integrins [106] to enhance nonviral transfection [107] . Additionally, we advocate a role for integrins in transfection because activating RAP1A, involved in integrin-mediated cell adhesion, increases transfection [44, 45] (with a role in transfection as discussed below).
ZDDHC13 was identified as another gene significantly downregulated in cells after 2 h of exposure to lipoplexes ( Figure 5 and Table 1) ; ZDDHC13 serves to palmitoylate membrane proteins in the Golgi apparatus and regulate membrane-to-membrane trafficking [108] or influence the interaction of membrane proteins within lipid rafts [109, 110] , including Ras GTPases such as RAP1A [109] . Because lipid rafts are associated with sites of endocytosis for lipoplexes [111, 112] , we hypothesized that activation (B-AGO-PCL, an inflammatory inducer and activator of MAP kinase and MAP kinase kinase) [65] or inhibition (nicergoline, α-adrenergic receptor antagonist and vasodilator) [62] of ZDDHC13 would lead to increased or decreased transfection, respectively. Activating ZDDHC13 resulted in a slight 1.1-fold decrease in transfection (Table 5 ) and did not support our hypothesis, suggesting that activation of ZDDHC13 may not be directly involved in transfection or that B-AGO-PCL is not suitable for testing our hypothesis. However, inhibiting ZDDHC13 resulted in a 1.9-fold decrease in transfection (Table 5) , which supports our hypothesis suggesting that disrupting the ability of the cell to enrich proteins to lipid rafts would probably lead to reduced endocytosis of lipoplexes and therefore reduced transfection. Increasing the concentration of either pharmacologic agent resulted in a cytotoxic effect (data not shown), suggesting that ZD-DHC13-mediated palmitoylation plays a larger role than just membrane trafficking of lipoplexes [113, 114] . The exact mechanism by which transfection is altered by inhibiting ZDDHC13 remains unknown and requires further investigation, although presumably because of the ability of ZDDHC13 to affect lipid rafts, the intracellular fate of the lipoplex cargo is also altered, which has been shown to drastically influence transfection [76, 91] . In summary, the activity of endogenous genes and pathways involved in filopodia protrusions (ALMS1, FCGR3A and DOCK10) , integrin signaling (ITGB1) and membrane trafficking (ZDDHC13) may affect transfection early in the DNA transfer process ( Figure 5 ).
Transfected cells overcome cell shutdown and barriers to transfection
As described above, 2 h after lipoplex delivery, all cells exhibited a 'shutdown,' as indicated by the highly downregulated nature of all differentially expressed genes (see Supporting information, Table S1 ). However, although not all cells eventually express the transgene, some cells do overcome the transcriptional shutdown event and express the transgene. Several cellular processes are known to occur over the course of the next hours (from internalization until transgene expression is detected) ( Figure 5 ), as shown by trafficking studies in the literature [21, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . What remains unknown are the molecules and pathways that participate in those processes, thereby preventing the rational design of enhanced nonviral gene delivery systems. By comparing gene expression profiles for transfected cells (GFP+) with untransfected cells (GFP-) over a time course of transfection, we were able to identify potential genes that may aid in overcoming barriers to transfection. Specifically, we targeted genes that occur in processes during DNA transfer 8, 16 and 24 h after delivery of lipoplexes, as described below (Figures 1 and 5 ).
Cellular processes that occur 8 h after exposure of lipoplexes to cells include endosomal escape [31, 33] , followed by unpacking of plasmid [31, 32] , nuclear localization [31, [33] [34] [35] [36] , nuclear entry [34, 36, 37] and a small amount of GFP synthesis [34, 38] . By comparing GFP+ and GFP-gene expression profiles, we found PACSIN3 and RAP1A genes to be upregulated at least five-fold, 8 h after exposure to lipoplexes ( Figure 5 and Table 3 ). PACSIN3 is a gene involved in proteolytic shedding of ectodomain receptors [115] , acting to reduce dynamin-mediated endocytosis [116] and involved in tubulin nucleation at the centrosome [117] . Given the gene product function, we hypothesized that activation (hydralazine hydrochloride, an inhibitor of membrane-bound enzymes) [62] or inhibition (valsartan, an angiotensin-receptor blocker) [64] of PACSIN3 would lead to decreased or increased transfection, respectively. Supporting our hypothesis, activating PACSIN3 resulted in a 1.3fold decrease in transfection presumably as a result of decreased endocytosis, which is the primary uptake route of lipoplexes into the cell [91] . Similarly, inhibiting PACSIN3 resulted in a 1.5-fold increase in transfection, probably a result of enhanced endocytosis of lipoplexes or stabilization of the microtubule network, which may enhance transport of lipoplexes to the cell nucleus [118] . The exact mechanism by which PACSIN3 affects nonviral transfection remains unclear but, given the processes that occur 8 h after delivery of lipoplexes and the putative function of PACSIN3, future studies should be conducted to determine the involvement of PACSIN3 in endocytosis of lipoplexes, nucleation and modification of the microtubule network, and potential enhancement in nuclear uptake of pDNA.
RAP1A was also overexpressed in the GFP+ to GFP-gene profile comparison after 8, 16 and 24 h of exposure of lipoplexes to the cells ( Figure 5 and Table 3 ). The results suggest that RAP1A plays a role in the cellular processes known to occur at those time points: 8 h (endosomal escape [31, 33] , followed by unpacking of plasmid [31, 32] , nuclear localization [31, [33] [34] [35] [36] , nuclear entry [34, 36, 37] and a small amount of GFP synthesis [34, 38] ); 16 h (nuclear localization [34] [35] [36] , nuclear entry [21, 34, 36, 37] and GFP synthesis [34, 38] ); and 24 h (2 mitosis [36, 39] , high nuclear plasmid number [34, 36, 37, 40] and the highest production of transgene [34, 38, 40] ). RAP1A is a small G protein (GTPase) that is activated by guanine nucleotide exchange factors, growth factors, cytokines and many other cell-surface receptors to act as a downstream effector promoting proliferation, cell survival, vesicular trafficking, cytoskeletal organization, integrin-mediated cell adhesion, increased proliferation, focal adhesions and phagocytosis [119, 120] . In our previous work, we found RAP1A to be upregulated at the 24-h time point in GFP+ cells relative to GFP-cells and that activating RAP1A prior to lipoplex delivery increased transfection two-fold [45] , probably affecting cellular processes known to affect transfection such as cell cycle [39] , cell survival [80, 102, 104] and endocytosis [111, 112] . In the present study, RAP1A continues to show a potential role in nonviral gene delivery because RAP1A was overexpressed at 8, 16 and 24 h when using the nonlinear method for calculating differential expression [51] (see Materials and methods). Two potential RAP1A activators (DOCK10 and ZDDHC13; see above) and three effectors (ALMS1, FCGR3A and ITGB1) were downregulated 2 h after exposure to lipoplexes. Given the 38.62-fold upregulation of RAP1A at the 8-h time point (Table 3) , it is possible that the cells able to overcome the transcriptional shutdown and achieve transfection may be those cells that do not exhibit a marked downregulation of DOCK10 or ZDDHC13 at the 2-h time point because activating those genes, as described above, would lead to enhanced transfection. During the 16-and 24-h time points, RAP1A could play a role in vesicular trafficking and cytoskeletal organization [119, 120] because activating RAP1A acts to acetylate microtubules, which could increase molecular trafficking of lipoplexes to the nucleus, and therefore lead to increased transfection [108] . Additionally, GTPase signaling transduction (e.g. DOCK10; see above) via cyclic adenosine monophosphate and protein kinase A can activate RAP1A, and protein kinase A has been recently shown to modulate intracellular routing of lipoplexes [121] . Taken together, a potential relationship among expression levels of RAP1Aactivators, RAP1A and RAP1A-effectors with cellular processes such as focal adhesion, integrin complex, migration, apoptosis, inflammation and cytoskeletal signaling may act together to affect DNA transfer ( Figure 5 ).
HSPA6 was also overexpressed in the GFP+ to GFP-gene profile comparison after 16 and 24 h of exposure of lipoplexes to the cells ( Figure 5 and Table 3 ). The results suggest that HSPA6 plays a role in the cellular processes noted to occur at those time points [21, [34] [35] [36] [37] [38] [39] [40] . HSPA6, heat shock 70-kDa protein 6 (HSP70B'), is primarily stress inducible and acts to maintain cell viability [122, 123] , although HSPA6 has also been shown to facilitate receptor-mediated endocytosis [124] , nuclear import of viral particles [125] and podia resorption [126] . In our previous work using linear models for differential expression determination, we found HSPA6 to be upregulated at the 24-h time point in GFP+ cells relative to GFP-cells and that activating HSPA6 prior to lipoplex delivery increased transfection by 2.5-fold [45] , probably by altering cellular processes that affect transfection such as nuclear import [125] , stabilization of transgene protein folding [122, 123] or podia resorption, which is tied to the cell cycle [126] . In the present study, HSPA6 continues to show a potential role in nonviral gene delivery because HSPA6 was overexpressed at 16h and again at 24 h when using the nonlinear method for calculating differential expression [51] (see Materials and methods). Taken together, HSPA6 may also be involved in nonviral transfection by affecting cellular processes such as cell stress/survival, cell cycle and the response to unfolded protein ( Figure 5 ). In summary, the genes and pathways identified in the present study provide a starting foundation for a preliminary model of the biology of transfection ( Figure 5 ), as well as for future studies to further determine the exact mechanism by which transfection is enhanced.
Conclusions
Identifying those genes and pathways that aid in overcoming barriers to transfection provides targets for engineering enhanced delivery systems and enabling their therapeutic use. In the present study, we began such an endeavor using microarrays to give a temporal and high throughput view of the genes and pathways that occur during DNA transfer when using lipoplexes, and extend our endeavor to polyplexes (in our complementary work) [48] . In the present study, treating cells with lipoplexes showed a transcriptional shutdown of genes involved in cell migration, the inflammatory response, adhesion and cell junctions, which appear to be important to DNA delivery because of their ability to modulate transfection. Possibly more important are the genes and pathways utilized by transfected cells to overcome cellular barriers to transfection. Those genes identified in the present study are involved in metabolism, stimuli response, cell adhesion, proliferation and membrane transport, and are able to modulate transfection. The genes, pathways and pharmacologic agents identified in the present study to alter transfection provide a basis to further explore mechanisms of DNA transfer, prime cells for enhanced transfection from existing DNA delivery strategies and engineer novel nonviral systems that can achieve enhanced transgene expression. In some cases, when conducting studies using artemisinin at a 1mM concentration (F), some locations in the well showed precipitation of the pharmacologic agent and minor toxicity to the cells. Minor toxicity was also observed when conducting studies using nifenazone at a 5mM concentration (N). 
